Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B
Omotola O Olasupo,Noella Noronha,Megan S Lowe,Derek Ansel,Mihir Bhatt,Davide Matino
DOI: https://doi.org/10.1002/14651858.cd014544.pub2
IF: 8.4
2024-02-28
Cochrane Database of Systematic Reviews
Abstract:Management of congenital hemophilia A and B is by prophylactic or on‐demand replacement therapy with clotting factor concentrates. The effects of newer non‐clotting factor therapies such as emicizumab, concizumab, marstacimab, and fitusiran compared with existing standards of care are yet to be systematically reviewed. To assess the effects (clinical, economic, patient‐reported, and adverse outcomes) of non‐clotting factor therapies for preventing bleeding and bleeding‐related complications in people with congenital hemophilia A or B compared with prophylaxis with clotting factor therapies, bypassing agents, placebo, or no prophylaxis. We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Coagulopathies Trials Register, electronic databases, conference proceedings, and reference lists of relevant articles and reviews. The date of the last search was 16 August 2023. Randomized controlled trials (RCTs) evaluating people with congenital hemophilia A or B with and without inhibitors, who were treated with non‐clotting factor therapies to prevent bleeds. Two review authors independently reviewed studies for eligibility, assessed risk of bias, and extracted data for the primary outcomes (bleeding rates, health‐related quality of life (HRQoL), adverse events) and secondary outcomes (joint health, pain scores, and economic outcomes). We assessed the mean difference (MD), risk ratio (RR), 95% confidence interval (CI) of effect estimates, and evaluated the certainty of the evidence using GRADE. Six RCTs (including 397 males aged 12 to 75 years) were eligible for inclusion. Prophylaxis versus on‐demand therapy in people with inhibitors Four trials (189 participants) compared emicizumab, fitusiran, and concizumab with on‐demand therapy in people with inhibitors. Prophylaxis using emicizumab likely reduced annualized bleeding rates (ABR) for all bleeds (MD −22.80, 95% CI −37.39 to −8.21), treated bleeds (MD −20.40, 95% CI −35.19 to −5.61), and annualized spontaneous bleeds (MD −15.50, 95% CI −24.06 to −6.94), but did not significantly reduce annualized joint and target joint bleeding rates (AjBR and AtjBR) (1 trial; 53 participants; moderate‐certainty evidence). Fitusiran also likely reduced ABR for all bleeds (MD −28.80, 95% CI −40.07 to −17.53), treated bleeds (MD −16.80, 95% CI −25.80 to −7.80), joint bleeds (MD −12.50, 95% CI −19.91 to −5.09), and spontaneous bleeds (MD −14.80, 95% CI −24.90 to −4.71; 1 trial; 57 participants; moderate‐certainty evidence). No evidence was available on the effect of bleed prophylaxis using fitusiran versus on‐demand therapy on AtjBR. Concizumab may reduce ABR for all bleeds (MD −12.31, 95% CI −19.17 to −5.45), treated bleeds (MD −10.10, 95% CI −17.74 to −2.46), joint bleeds (MD −9.55, 95% CI −13.55 to −5.55), and spontaneous bleeds (MD −11.96, 95% CI −19.89 to −4.03; 2 trials; 78 participants; very low‐certainty evidence), but not target joint bleeds (MD −1.00, 95% CI −3.26 to 1.26). Emicizumab prophylaxis resulted in an 11.31‐fold increase, fitusiran in a 12.5‐fold increase, and concizumab in a 1.59‐fold increase in the proportion of participants with no bleeds. HRQoL measured using the Haemophilia Quality of Life Questionnaire for Adults (Haem‐A‐QoL) physical and total health scores was improved with emicizumab, fitusiran, and concizumab prophylaxis (low‐certainty evidence). Non‐serious adverse events were higher with non‐clotting factor therapies versus on‐demand therapy, with injection site reactions being the most frequently reported adverse events. Transient antidrug antibodies were reported for fitusiran and concizumab. Prophylaxis versus on‐demand therapy in people without inhibitors Two trials (208 participants) compared emicizumab and fitusiran with on‐demand therapy in people without inhibitors. One trial assessed two doses of emicizumab (1.5 mg/kg weekly and 3.0 mg/kg bi‐weekly). Fitusiran 80 mg monthly, emicizumab 1.5 mg/kg/week, and emicizumab 3.0 mg/kg bi‐weekly all likely resulted in a large reduction in ABR for all bleeds, all treated bleeds, and joint bleeds. AtjBR was not reduced with either of the emicizumab dosing regimens. The effect of fitusiran prophylaxis on target joint bleeds was not assessed. Spontaneous bleeds were likely reduced with fitusiran (MD −20.21, 95% CI –32.12 to −8.30) and emicizumab 3.0 mg/kg bi‐weekly (MD −15.30, 95% CI −30.46 to −0.14), but not with emicizumab 1.5 mg/kg/week (MD –14.60, 95% CI –29.78 to 0.58). The percentage of participants with zero bleeds was higher following emicizumab 1.5 mg/kg/week (50% versus 0%), emicizumab 3.0 mg/kg bi‐weekly (40% versus 0%), and fitusiran prophylaxis (40% versus 5%) compared with on‐demand therapy. Emicizumab 1.5 mg/kg/week did not improve Haem‐A‐QoL physical and total health scores, EQ‐5D‐5L VAS, or utility index scores (low‐certainty evidence) when compared with on‐demand therapy at 25 weeks. Emicizum -Abstract Truncated-
medicine, general & internal